Coherus Oncology
CHRS
Coherus Oncology (CHRS) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Guggenheim | Maintained | Buy | $10.00 from $12.00 | Aug 7, 2026 |
| Guggenheim | Initiated Coverage | Buy | $12.00 | May 11, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $10.00 | Jan 22, 2026 |
| Maxim Group | Upgraded | Hold → Buy | $4.00 | Sep 4, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Apr 29, 2025 |
| UBS | Maintained | Neutral | $1.05 from $1.50 | Apr 24, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Mar 11, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Jan 23, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Jan 22, 2025 |
| Baird | Maintained | Outperform | $6.00 from $4.00 | Dec 5, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Dec 4, 2024 |
| Baird | Maintained | Outperform | $4.00 from $8.00 | Nov 8, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $12.00 | Nov 7, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $12.00 | Sep 16, 2024 |
| UBS | Downgraded | Buy → Neutral | $1.50 from $4.00 | Aug 16, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $12.00 | Aug 5, 2024 |
| Baird | Maintained | Outperform | $8.00 from $9.00 | Jul 1, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $12.00 | May 24, 2024 |
| Truist Securities | Maintained | Buy | $7.00 from $8.00 | May 13, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $12.00 from $11.00 | May 10, 2024 |
Frequently asked questions
What is the latest analyst rating on CHRS?
On Aug 7, 2026, Guggenheim maintained Coherus Oncology at Buy with a price target of $10.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.